Patents by Inventor Denise Barbut

Denise Barbut has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190381071
    Abstract: This invention relates to methods of treating and/or preventing the progression and/or onset of age-related neurodegeneration. The invention also relates to methods of reversibly slowing the growth and/or aging of a subject, and/or extending the potential lifespan of the subject, comprising administration of the naturally occurring aminosterol MSI-1436, or derivatives or salts thereof. Also described are methods of treating, preventing or delaying the onset of age-related diseases or conditions comprising administration of Aminosterol 1436, or derivatives or salts thereof.
    Type: Application
    Filed: June 13, 2019
    Publication date: December 19, 2019
    Applicant: Enterin, Inc.
    Inventors: Michael Zasloff, Denise Barbut
  • Publication number: 20190298740
    Abstract: This application relates to methods of treating, preventing and/or slowing the onset or progression of hallucinations and/or related symptoms caused by a variety disorders, with aminosterols or pharmaceutically acceptable salts or derivatives thereof.
    Type: Application
    Filed: March 25, 2019
    Publication date: October 3, 2019
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff
  • Publication number: 20190127416
    Abstract: Provided herein are crystalline solid forms of squalamine phosphate designated as Form 1 and Form 2, compositions containing one or both forms, and methods of their preparation and of their use.
    Type: Application
    Filed: October 26, 2018
    Publication date: May 2, 2019
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff
  • Publication number: 20190091241
    Abstract: This invention relates to methods of treating or preventing a sleep disorder, sleep disturbance, or related symptom in a subject with aminosterols or pharmaceutically acceptable salts or derivatives thereof. In particular, the disclosed methods generally comprise administering an aminosterol to a subject in need, thereby stimulating an aminosterol-induced CNS response to treat and/or prevent a sleep disorder, sleep disturbance, or related symptom.
    Type: Application
    Filed: September 5, 2018
    Publication date: March 28, 2019
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff
  • Publication number: 20180344748
    Abstract: Described are methods of treating or preventing an inflammatory disease or condition caused by excessive expression, secretion, or concentration of alpha synuclein. The methods comprise administering compositions that reduce the effective concentration of alpha-synuclein present in the surrounding tissues. In addition, the invention encompasses methods of inhibiting alpha-synuclein interaction with CD11b, comprising administering an agent that binds to alpha-synuclein to prevent binding productively to the integrin CD11b, or administering an active agent that interacts with CD11b on an immune cell to prevent alpha-synuclein from directing chemotaxis of that cell. In addition, the invention discloses a method of identifying an individual with a condition amenable to treatment targeting alpha-synuclein CD11b interaction.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Applicant: ENTERIN LABORATORIES, INC.
    Inventors: Denise Barbut, Ethan Stolzenberg, Michael Zasloff
  • Patent number: 9775741
    Abstract: Methods for cerebral cooling are described. Cooling assemblies include elongate tubular members, a reservoir containing a pressurized fluid, and a manifold connecting the reservoir and elongate tubular members. After insertion of the elongate tubular members into the patient's nostrils, a pressurized fluid is delivered onto a surface of the patient's nasal cavity through a plurality of ports in the elongate tubular members. The delivery of the fluid causes cooling by direct heat transfer through the nasopharynx and hematogenous cooling through the carotids and the Circle of Willis.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: October 3, 2017
    Assignee: BrainCool AB
    Inventors: Denise Barbut, Alan Rozenberg, John K Hoffman, Thomas H Shaffer
  • Publication number: 20170027745
    Abstract: Devices for cerebral and systemic cooling via a patient's nasopharyngeal cavity are described. Cooling assemblies include at least one elongate tubular member having first and second lumens, a source of liquid coolant, a gas source communicating with the first lumen, and a switch for alternately connecting the liquid coolant source to the second lumen. The first lumen transports a compressed gas and the second lumen transports a volatile liquid. The pressurized fluid may be a perflurocarbon. The perfluorocarbon may be perfluorohexane, perfluoropentane, or 2-methyl-perfluoropentane. The gas may be air, oxygen, or a combination.
    Type: Application
    Filed: June 2, 2016
    Publication date: February 2, 2017
    Inventors: Allan ROZENBERG, Denise BARBUT, John K. HOFFMAN, Thomas H. SHAFFER
  • Patent number: 9358150
    Abstract: Methods for cerebral and systemic cooling via a patient's nasopharyngeal cavity are described. In one method, a cooling assembly is inserted into a nasal cavity through a patient's nostril. A substantially dry gas is delivered through a lumen of the catheter onto the surface of the patient's nasal cavity. Evaporative heat loss cools the patient's nasal cavity. If additional cooling is needed, a liquid coolant is delivered through a separated lumen of the catheter. The liquid coolant is nebulized at a plurality of delivery ports on the distal end of the catheter and is delivered onto the surface of the patient's nasal cavity in combination with the dry gas. The dry gas enhances evaporation of the nebulized coolant and additional cooling is provided from the evaporative heat loss of the liquid coolant.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: June 7, 2016
    Assignee: BeneChill, Inc.
    Inventors: Allan Rozenberg, Denise Barbut, John K Hoffman, Thomas H Shaffer
  • Patent number: 9265922
    Abstract: A system for improving outcome following cerebral ischemia is provided. The system includes a source of nitric oxide and an elongate tubular member for insertion into a nose including at least one orifice thereon. The elongate tubular member is coupled to the source of nitric oxide and configured for delivering the nitric oxide into a nasal cavity through the at least one orifice for absorption into a cerebral vasculature through a nasal vasculature. A device for controlling flow of the gas, a concentration of the nitric oxide in the gas, or both, is also provided.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: February 23, 2016
    Assignee: ASTUCE, INC.
    Inventors: Denise Barbut, Allan Rozenberg, Axel Heinemann
  • Publication number: 20150273011
    Abstract: A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg, alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist.
    Type: Application
    Filed: October 10, 2014
    Publication date: October 1, 2015
    Applicants: SARENTIS THERAPEUTICS, INC., MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: DENISE BARBUT, Gavril W. Pasternak, Elliott Richelson
  • Publication number: 20150080314
    Abstract: Ocular analgesics for topical administration are described. The topical ocular analgesic includes a neo-tryptophan-containing neurotensin analog. The topical ocular analgesic may alternatively include a buffered salt solution, a local anesthetic solution, a tissue penetrating agent, and/or an opiate. The neo-tryptophan-containing neurotensin analog may be present in a dose of about 0.0005 to about 1.2 mg.
    Type: Application
    Filed: April 4, 2014
    Publication date: March 19, 2015
    Applicants: Sarentis Therapeutics, Inc., Mayo Foundation for Medical Education and Research, Sloan-Kettering Institute for Cancer Research
    Inventors: DENISE BARBUT, Gavril W. Pasternak, Elliott Richelson
  • Publication number: 20140343641
    Abstract: Methods for cerebral cooling are described. Cooling assemblies include elongate tubular members, a reservoir containing a pressurized fluid, and a manifold connecting the reservoir and elongate tubular members. After insertion of the elongate tubular members into the patient's nostrils, a pressurized fluid is delivered onto a surface of the patient's nasal cavity through a plurality of ports in the elongate tubular members. The delivery of the fluid causes cooling by direct heat transfer through the nasopharynx and hematogenous cooling through the carotids and the Circle of Willis.
    Type: Application
    Filed: April 30, 2014
    Publication date: November 20, 2014
    Applicant: BENECHILL, INC.
    Inventors: Denise Barbut, Alan Rozenberg, John K. Hoffman
  • Patent number: 8840636
    Abstract: Devices and methods for filtering blood. The devices generally comprise a mesh for filtering blood flowing within a blood vessel, particularly within an artery such as the aorta, a structure adapted to open and close the mesh within the blood vessel, and a device or method to actuate the structure. The methods generally include the steps of introducing a mesh into a blood vessel to entrap emboli material, and removing the mesh and the entrapped foreign matter from the blood vessel.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: September 23, 2014
    Assignee: Edwards Lifesciences Corporation
    Inventors: Denise Barbut, Tracy D. Maahs
  • Patent number: 8721699
    Abstract: A method for providing and adjusting cerebral cooling in response to changes in a physiological parameter. A spray having a boiling point between 38-300° C. is delivered to the surface of a patient's nasal cavities. The spray causes cooling by direct heat transfer through the nasopharynx and hematogenous cooling through the carotids and the Circle of Willis. A physiological parameter, such as cerebral temperature, changes in cerebral blood flow or brain oxygenation is monitored. The delivery rate of the spray is adjusted in response to the physiological parameter.
    Type: Grant
    Filed: February 10, 2010
    Date of Patent: May 13, 2014
    Assignee: BeneChill, Inc.
    Inventors: Denise Barbut, Allan Rozenberg, John K Hoffman
  • Publication number: 20140088562
    Abstract: A method of modulating a physiological parameter of a patient is provided. The method includes disabling one or more pre-aortic ganglion cells within a pre-aortic ganglion and improving the physiological parameter. The method further includes destroying a pre-aortic ganglion cell to prevent regeneration.
    Type: Application
    Filed: November 4, 2013
    Publication date: March 27, 2014
    Inventors: Denise Barbut, Allan Rozenberg, Axel Heinemann
  • Publication number: 20130331813
    Abstract: A method of modulating a physiological parameter of a patient by percutaneously or transcutaneously disabling one or more pre-aortic ganglion cells within a pre-aortic ganglion via the anterior abdominal wall and improving the physiological parameter is provided. The pre-aortic ganglion cells may be disabled by applying radiofrequency, high intensity or low intensity focused ultrasound.
    Type: Application
    Filed: March 14, 2013
    Publication date: December 12, 2013
    Applicant: ENIGMA MEDICAL, INC.
    Inventors: Denise Barbut, Allan Rozenberg, Axel Heinemann
  • Publication number: 20130302445
    Abstract: A non-invasive method of treating cerebral ischemia, involving the use of non-inhaled, intra-nasally delivered carbon dioxide (CO2), alone or in combination with other gases to augment cerebral perfusion and improve outcome following a stroke is provided. A vasodilator gas is delivered intranasally, alone or in combination with a second gas, for prolonged periods of time without systemic absorption. The second gas may be selected from NO, hydrogen, xenon, anesthetic gases, oxygen, nitrogen, nitrous oxide, carbon monoxide, or air. The treatment selectively increases cerebral perfusion and provides neuroprotection in the treatment of cerebral ischemia.
    Type: Application
    Filed: April 16, 2013
    Publication date: November 14, 2013
    Inventors: Denise Barbut, Allan Rozenberg, Axel Heinemann
  • Publication number: 20130296443
    Abstract: A method of modulating a physiological parameter of a patient is provided. The method includes disabling one or more pre-aortic ganglion cells within a pre-aortic ganglion trans-venously and improving the physiological parameter. The method further includes destroying a pre-aortic ganglion cell trans-venously to prevent regeneration.
    Type: Application
    Filed: March 6, 2013
    Publication date: November 7, 2013
    Applicant: ENIGMA MEDICAL, INC.
    Inventors: Denise Barbut, Allan Rozenberg, Axel Heinemann
  • Publication number: 20130296646
    Abstract: A method of ablating the sympathetic ganglionic cell bodies in the thoracic paravertebral space is provided. The method includes ablating the sympathetic ganglionic cell bodies in the thoracic paravertebral space through a posterior, non-invasive or minimally invasive approach for the treatment of resistant hypertension. The ablation may additionally involve various permutations of the gray and white rami and the dorsal root ganglion in addition to the sympathetic chain ganglionic cell bodies, all located in the triangular paravertebral space.
    Type: Application
    Filed: March 6, 2013
    Publication date: November 7, 2013
    Applicant: Enigma Medical, Inc.
    Inventors: Denise Barbut, Allan Rozenberg, Axel Heinimann
  • Publication number: 20130296836
    Abstract: A method of modulating a physiological parameter of a patient is provided. The method includes disabling one or more pre-aortic ganglion cells within a pre-aortic ganglion and improving the physiological parameter. The method further includes destroying a pre-aortic ganglion cell to prevent regeneration.
    Type: Application
    Filed: March 6, 2013
    Publication date: November 7, 2013
    Applicant: ENIGMA MEDICAL, INC.
    Inventors: Denise Barbut, Allan Rozenberg, Axel Heinemann